



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/393022/2013

European Medicines Agency decision

P/0183/2013

of 31 July 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ferric citrate (EMA-001213-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0183/2013

of 31 July 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ferric citrate (EMA-001213-PIP02-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Keryx Biopharmaceuticals, Inc. on 5 November 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 June 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ferric citrate, film-coated tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ferric citrate, film-coated tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ferric citrate, film-coated tablet, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Keryx Biopharmaceuticals, Inc., 750 Lexington Ave. - 20th Floor, NY 10022 New York, United States.

Done at London, 31 July 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/196096/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001213-PIP02-12

Scope of the application

Active substance(s):

Ferric citrate

Condition(s):

Treatment of hyperphosphataemia

Pharmaceutical form(s):

Film-coated tablet

Powder for oral suspension

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Keryx Biopharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Keryx Biopharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 5 November 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 12 December 2012.

Supplementary information was provided by the applicant on 22 March 2013. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 14 June 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of hyperphosphataemia

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- for film-coated tablet, powder for oral suspension, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition: treatment of hyperphosphataemia

2.1.1. Indication(s) targeted by the PIP

Treatment of hyperphosphataemia in patients with chronic kidney disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Powder for oral suspension

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1: Development of a powder for oral suspension.
Non-clinical	1	Measure 2: 56-Day oral toxicity study in juvenile rats.
Clinical	1	Measure 3: Open-label, randomised, multi-centre, active controlled trial to evaluate safety and efficacy of ferric citrate in children from 6 months to less than 18 years of age with hyperphosphataemia related to chronic kidney disease (CKD).

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes